|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Denny L, de Sanjose S, Mutebi M, Anderson
BO, Kim J, Jeronimo J, Herrero R, Yeates K, Ginsburg O and
Sankaranarayanan R: Interventions to close the divide for women
with breast and cervical cancer between low-income and
middle-income countries and high-income countries. Lancet.
389:861–870. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Waggoner SE: Cervical cancer. Lancet.
361:2217–2225. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Molano M, Moreno-Acosta P, Morales N,
Burgos M, Buitrago L, Gamboa O, Alvarez R, Garland SM, Tabrizi SN,
Steenbergen RD and Mejía JC: Association between type-specific HPV
infections and hTERT DNA methylation in patients with invasive
cervical cancer. Cancer Genomics Proteomics. 13:483–491. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schiffman M and Solomon D: Clinical
practice. Cervical-cancer screening with human papillomavirus and
cytologic cotesting. N Engl J Med. 369:2324–2331. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Muñoz N, Franceschi S, Bosetti C, Moreno
V, Herrero R, Smith JS, Shah KV, Meijer CJ and Bosch FX;
International Agency for Research on Cancer, ; Multicentric
Cervical Cancer Study Group, : Role of parity and human
papillomavirus in cervical cancer: The IARC multicentric
case-control study. Lancet. 359:1093–1101. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rauh-Hain JA, Clemmer JT, Bradford LS,
Clark RM, Growdon WB, Goodman A, Boruta DM II, Schorge JO and del
Carmen MG: Racial disparities in cervical cancer survival over
time. Cancer. 119:3644–3652. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sizemore ST and Keri RA: The forkhead box
transcription factor FOXC1 promotes breast cancer invasion by
inducing matrix metalloprotease 7 (MMP7) expression. J Biol Chem.
287:24631–24640. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xia L, Huang W, Tian D, Zhu H, Qi X, Chen
Z, Zhang Y, Hu H, Fan D, Nie Y and Wu K: Overexpression of forkhead
box C1 promotes tumor metastasis and indicates poor prognosis in
hepatocellular carcinoma. Hepatology. 57:610–624. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun J, Ishii M, Ting MC and Maxson R:
Foxc1 controls the growth of the murine frontal bone rudiment by
direct regulation of a Bmp response threshold of Msx2. Development.
140:1034–1044. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jin Y, Han B, Chen J, Wiedemeyer R,
Orsulic S, Bose S, Zhang X, Karlan BY, Giuliano AE, Cui Y and Cui
X: FOXC1 is a critical mediator of EGFR function in human
basal-like breast cancer. Ann Surg Oncol. 21 Suppl 4:S758–S766.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu ZY, Ding SM, Zhou L, Xie HY, Chen KJ,
Zhang W, Xing CY, Guo HJ and Zheng SS: FOXC1 contributes to
microvascular invasion in primary hepatocellular carcinoma via
regulating epithelial-mesenchymal transition. Int J Biol Sci.
8:1130–1141. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wei LX, Zhou RS, Xu HF, Wang JY and Yuan
MH: High expression of FOXC1 is associated with poor clinical
outcome in non-small cell lung cancer patients. Tumour Biol.
34:941–946. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song Y, Washington MK and Crawford HC:
Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal
transition in pancreatic cancer. Cancer Res. 70:2115–2125. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ray PS, Wang J, Qu Y, Sim MS, Shamonki J,
Bagaria SP, Ye X, Liu B, Elashoff D, Hoon DS, et al: FOXC1 is a
potential prognostic biomarker with functional significance in
basal-like breast cancer. Cancer Res. 70:3870–3876. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saslow D, Solomon D, Lawson HW, Killackey
M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur
DC, et al: American Cancer Society, American Society for Colposcopy
and Cervical Pathology, and American Society for Clinical Pathology
screening guidelines for the prevention and earlydetection of
cervical cancer. Am J Clin Pathol. 137:516–542. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu T, Chen X, Peng R, Liu H, Yin P, Peng
H, Zhou Y, Sun Y, Wen L, Yi H, et al: Let7a suppresses cell
proliferation via the TGF-β/SMAD signaling pathway in cervical
cancer. Oncol Rep. 36:3275–3282. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ou-Yang L, Xiao SJ, Liu P, Yi SJ, Zhang
XL, Ou-Yang S, Tan SK and Lei X: Forkhead box C1 induces
epithelial-mesenchymal transition and is a potential therapeutic
target in nasopharyngeal carcinoma. Mol Med Rep. 12:8003–8009.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Han B, Qu Y, Jin Y, Yu Y, Deng N,
Wawrowsky K, Zhang X, Li N, Bose S, Wang Q, et al: FOXC1 activates
smoothened-independent hedgehog signaling in basal-like breast
cancer. Cell Rep. 13:1046–1058. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen S, Jiao S, Jia Y and Li Y: Effects of
targeted silencing of FOXC1 gene on proliferation and in vitro
migration of human non-small-cell lung carcinoma cells. Am J Transl
Res. 8:3309–3318. 2016.PubMed/NCBI
|
|
22
|
Wang J, Ray PS, Sim MS, Zhou XZ, Lu KP,
Lee AV, Lin X, Bagaria SP, Giuliano AE and Cui X: FOXC1 regulates
the functions of human basal-like breast cancer cells by activating
NF-κB signaling. Oncogene. 31:4798–4802. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang J, Li L, Liu S, Zhao Y, Wang L and Du
G: FOXC1 promotes melanoma by activating MST1R/PI3K/AKT.
Oncotarget. 7:84375–84387. 2016.PubMed/NCBI
|
|
24
|
Wang Z, Qu L, Deng B, Sun X, Wu S, Liao J,
Fan J and Peng Z: STYK1 promotes epithelial-mesenchymal transition
and tumor metastasis in human hepatocellular carcinoma through
MEK/ERK and PI3K/AKT signaling. Sci Rep. 6:332052016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang J, Qin G, Luo M, Chen J, Zhang Q, Li
L, Pan L and Qin S: Reciprocal positive regulation between Cx26 and
PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC
cells via GJIC-independent induction of EMT. Cell Death Dis.
6:e18292015. View Article : Google Scholar : PubMed/NCBI
|
